EUVIMEDEUVIMED entdecken
Crossref

Directed Evolution of AAV9 for Efficient Gene Expression in Cardiomyocytes In Vitro and In Vivo

Leonard Hüttermann iD, Lena C Schröder, Prithviraj M V Shetty, Timo Jonker, Susanne S Hille, Anca Kliesow Remes, Andrea Matzen, Arie R Boender, Dirk Grimm iD, Derk Frank, Gerard J J Boink, Thomas Eschenhagen iD und 2 weitere

Human Gene Therapy · 2025

DOI: 10.1089/hum.2024.126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Leonard Hüttermann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine V, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Dependovirus, Myocytes, Cardiac, Genetic Vectors, Gene Expression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adeno-associated viral (AAV) vectors are increasingly used for preclinical and clinical cardiac gene therapy approaches. However, gene transfer to cardiomyocytes poses a challenge due to differences between AAV serotypes in terms of expression efficiency in vitro and in vivo. For example, AAV9 vectors work well in rodent heart muscle cells in vivo but not in cultivated neonatal rat ventricular cardiomyocytes (NRVCMs), necessitating the use of AAV6 vectors for in vitro studies. Therefore, we aimed to develop an AAV that could efficiently express genes in NRVCMs, human engineered heart tissue (hEHT), and mammalian hearts. The production of AAV6 vectors results in lower yields compared with AAV9. Hence, we used random AAV9 peptide libraries and selected variants on NRVCMs at the vector genome and RNA levels in parallel. The enriched library variants were characterized using high-throughput analysis of barcoded variants, followed by individual validation of the most promising candidates. Interestingly, we found striking differences in NRVCM transduction and gene expression patterns of the AAV capsid variants depending on the selection strategy. AAV variants selected based on the vector genome level enabled the highest transduction but were outperformed by AAVs selected on the RNA level in terms of expression efficiency. In addition, we identified a new AAV9 capsid variant that not only allowed significantly higher gene expression in NRVCMs compared with AAV6 but also enabled similar gene expression in murine hearts as AAV9 wild-type vectors after being intravenously injected into mice. Moreover, the novel variant facilitated significantly higher gene expression in hEHT compared with AAV9. Therefore, this AAV variant could streamline preclinical gene therapy studies of myocardial diseases by eliminating the need for using different AAVs for NRVCMs, hEHT, and mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusMyocytes, CardiacGenetic VectorsGene ExpressionDirected Molecular EvolutionAnimalsHumansRatsTransduction, GeneticGenetic TherapyMiceCapsid Proteins

Stichwörter der Autor:innen

AAV9NRVCMcardiac-specificgene therapyhiPSC-CMpeptide library selection

Substanzen

Capsid Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine V, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany.
  • German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
  • Department of Medical Biology and Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • PacingCure B.V., Amsterdam, The Netherlands.
  • Department of Infectious Diseases/Virology, Section Viral Vector Technologies, Medical Faculty and Faculty of Engineering Sciences, BioQuant, German Centre for Infection Research (DZIF) and German Centre for Cardiovascu…
  • Department of Internal Medicine III, University Hospital Schleswig-Holstein and University of Kiel, Kiel, Germany.

ORCID-Profile: Leonard Hüttermann, Dirk Grimm, Thomas Eschenhagen, Oliver J Müller

Zitieren

APA

Hüttermann, L., Schröder, L. C., Shetty, P. M. V., Jonker, T., Hille, S. S., Kliesow Remes, A., Matzen, A., Boender, A. R., Grimm, D., Frank, D., Boink, G. J. J., Eschenhagen, T., Schade, D., & Müller, O. J. (2025). Directed Evolution of AAV9 for Efficient Gene Expression in Cardiomyocytes In Vitro and In Vivo. Human Gene Therapy. https://doi.org/10.1089/hum.2024.126

Vancouver

Hüttermann L, Schröder LC, Shetty PMV, Jonker T, Hille SS, Kliesow Remes A, et al. Directed Evolution of AAV9 for Efficient Gene Expression in Cardiomyocytes In Vitro and In Vivo. Human Gene Therapy. 2025. doi:10.1089/hum.2024.126

BibTeX
@article{Httermann2025,
  author = {Hüttermann, Leonard and Schröder, Lena C and Shetty, Prithviraj M V and Jonker, Timo and Hille, Susanne S and Kliesow Remes, Anca and Matzen, Andrea and Boender, Arie R and Grimm, Dirk and Frank, Derk and Boink, Gerard J J and Eschenhagen, Thomas and Schade, Dennis and Müller, Oliver J},
  title = {Directed Evolution of AAV9 for Efficient Gene Expression in Cardiomyocytes In Vitro and In Vivo},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1089/hum.2024.126}
}
Kostenlos starten →